High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
We administered high-dose mitoxantrone in combination with etoposide to 6 patients with relapsed Hodgkin's disease as the conditioning regimen for autologous bone marrow transplantation. This regimen was well tolerated and no significant cardiotoxicity was observed. Responses of the Hodgkin's disease to this therapy were favourable but short-lived. Serial measurements of the serum levels of mitoxantrone suggested an open 3-compartment model of drug distribution. The rapid early phase of drug distribution was followed by an intermediate phase and a slow terminal drug-elimination phase. However, mitoxantrone was still detected in the serum of all patients 7 days after the last dose of mitoxantrone and on the day of bone marrow re-infusion. The clinical significance of such findings is unclear but they may suggest a need for the use of other anthracycline-related cytotoxic agents for the conditioning in autologous bone marrow transplantation.
Lim
S H
SH
Department of Haematology, Addenbrooke's Hospital, Cambridge, U.K.
Baglin
T P
TP
Flavell
D J
DJ
Flavell
S U
SU
Wimperis
J Z
JZ
Marcus
R E
RE
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D012074:Remission Induction; D016879:Salvage Therapy
D005047:Etoposide; D008942:Mitoxantrone